{"nctId":"NCT01748292","briefTitle":"Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab","startDateStruct":{"date":"2012-12","type":"ACTUAL"},"conditions":["Macular Degeneration"],"count":60,"armGroups":[{"label":"Monthly IVT ranibizumab","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: 0.5 mg ranibizumab"]},{"label":"Treat and Extend IVT ranibizumab","type":"EXPERIMENTAL","interventionNames":["Drug: 0.5 mg ranibizumab"]}],"interventions":[{"name":"0.5 mg ranibizumab","otherNames":["Lucentis"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Ability to provide written informed consent and comply with study assessments for the full duration of the study\n* Age \\> 50 years\n* Ability and willingness to return for all scheduled visits and assessments\n* Any CNVM lesion (Occult, Minimally Classic or Classic) (i.e., leakage on fluorescein angiography or subretinal, intraretinal activity on SDOCT) secondary to age-related macular degeneration.\n\nBest corrected visual acuity in the study eye, using ETDRS testing, between 20/32 and 20/400 (Snellen equivalent), inclusive.\n\n-The total area of subretinal hemorrhage and fibrosis must comprise less than 50% of the total lesion. Clear ocular media and adequate pupillary dilation to permit good quality fundus imaging.\n\nExclusion Criteria:\n\n* Subretinal hemorrhage in the study eye that involves the center of the fovea, if the size of the hemorrhage is either \\> 50% of the total area of the lesion or \\> 1 disc area (2.54 mm2) in size\n* Subfoveal fibrosis or atrophy in the study eye\n* CNV in either eye due to other causes, such as ocular histoplasmosis, trauma, or pathologic myopia","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change in BCVA by ETDRS Letter Score From Baseline","description":"Mean change in Best-Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) letter score from baseline through weeks 24-28, baseline through weeks 48-56, baseline through weeks 72-82, baseline to week 104, baseline through weeks 128-132 and baseline to week 156. The ETDRS protocol is a widely accepted international standard for macular laser photocoagulation treatment. A higher score represents better functioning. The scale ranges from 0 to 100 letters","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":"1.3"},{"groupId":"OG001","value":"7.3","spread":"1.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","spread":"1.4"},{"groupId":"OG001","value":"10.5","spread":"2.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":"1.9"},{"groupId":"OG001","value":"9.0","spread":"3.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":"1.9"},{"groupId":"OG001","value":"8.7","spread":"3.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":"2.3"},{"groupId":"OG001","value":".95","spread":"4.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":"2.8"},{"groupId":"OG001","value":"4.1","spread":"4.0"}]}]}]},{"type":"SECONDARY","title":"Incidence and Severity of Adverse Events (Ocular and Non-ocular)","description":"Incidence and severity of adverse events both ocular and non-ocular","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Number of Intravitreal Injections Required","description":"Total number of intravitreal injections required from baseline through weeks 48-57 (week closest to week 52), baseline through week 104 and baseline through week 156.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":null},{"groupId":"OG001","value":"10.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.5","spread":null},{"groupId":"OG001","value":"18.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.5","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Number of Office Visits and Imaging Studies Performed During Study Period","description":"Total number of office visits and imaging studies performed from baseline through weeks 24-28 (week closest to week 26), baseline through weeks 48-56 (week closest to week 52), baseline through weeks 72-82 (week closest to week 78), baseline through week 104, baseline through weeks 128-132 (week closest to week 132) and baseline through week 156","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"262","spread":null},{"groupId":"OG001","value":"364","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"560","spread":null},{"groupId":"OG001","value":"838","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"801","spread":null},{"groupId":"OG001","value":"1143","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Persistent Active Exudation on SD-OCT","description":"Percentage of subjects with persistent active exudation on SD-OCT from baseline through weeks 48-57 (week closest to week 52), baseline through week 104 and baseline through week 156.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change in Central Foveal Thickness","description":"Mean change in central foveal thickness by SD-OCT from baseline to weeks 48-57, baseline to week 104 and baseline to week 156.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-246","spread":"43"},{"groupId":"OG001","value":"-173","spread":"31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-170","spread":"37"},{"groupId":"OG001","value":"-170","spread":"37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-188","spread":"42"},{"groupId":"OG001","value":"-183","spread":"32"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Persistent Leakage on Fluorescein Angiography","description":"Percentage of subjects with persistent leakage on fluorescein angiography from baseline through weeks 24-28, baseline to weeks 48-56, baseline to weeks 72-82, baseline to week 104, baseline to weeks 128- 132 and baseline to week 156.","classes":[]},{"type":"SECONDARY","title":"CNVM Lesion Size","description":"CNVM lesion size at baseline, compared to baseline to weeks 24-28, baseline to weeks 48-56, baseline to weeks 72-82, baseline to week 104, baseline to weeks 128-132 and baseline to week 156, as determined by fluorescein angiography.","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":20},"commonTop":["Progressive macular atrophy","Subretinal hemorrhage","Hollenhorst plaque"]}}}